Course : MOC Part II: Clinical Biochemical Genetics Literature Review (Issue 2017)
The Literature Review modules are comprised of 5-8 current and relevant literature articles in this specialty. The topics encompass new clinical applications or methodologies, diagnostic methods and approaches, management and treatment of genetic conditions, and relevant practice guidelines.
Diplomates are required to complete one Part II literature review module per 3 year timeframe of their ABMGG Continuing Certification MOC program.
New modules will be posted every two years. Each module will be available for a three-year period of time, so that up to two modules will be available at any given time.
Each literature review module consists of:
- Optional pre-reading test - Diplomates can take a 25 question pre-test. The score of the pre-test is revealed to the test taker only and a passing score does not exempt the diplomate from taking the post-test.
- Set of required reading -Full citations for five to eight specialty-specific articles will be listed.
- Post-reading test - Consists of the same 25 multiple-choice questions as the pre-test. Responses are scored immediately. Diplomates who do not achieve a passing score of 80% may repeat the test until a passing score is attained.
Date of Release: August 28th, 2017
Expiration Date: December 31, 2020
Estimate Time of Completion: 8 hours
Course must be completed by the expiration dates
Registration and Fees
CME Credits and MOC Part II Certificate ($25)
MOC Part II Certificate Only ABMGG Diplomates ($0/no cost)
At the conclusion of this course, participants should be able to:
1. Describe how reference ranges for biochemical testing are relevant for test interpretation when samples are obtained under stressed conditions.
2. List and elaborate on the "real world" analytical and interpretation challenges that will arise from implementation of lysosomal storage disorder newborn screening.
3. Describe how newly described alterations in genes controlling lipoic acid synthesis produce phenotypes overlapping those seen in primary deficiencies of the cofactor dependent enzyme complex.
4. Describe how untargeted metabolomics analysis can be applied to clinical screening and diagnosis of inborn errors of metabolism, and list the determinants to be considered when evaluating these new technologies.
5. Describe how gene discovery through exome analysis can explain unexpected phenotypic findings in an inborn error of metabolism and unexpected mechanisms of disease.